Inhibitor of inflammasome activation
To provide a novel inflammasome inhibitor capable of inhibiting activation of inflammasome, the present inventors newly found that arctigenin reduces the amount of 1L-1β released and the amount of activated caspase-1 upon stimulation with ATP, palmitic acid, MSU and Poly(dA:dT) and thus has an effect of inhibiting inflammasome activation. The present invention provides an inhibitor of inflammasome activation that comprises arctigenin as an active ingredient.
1. A method for treating or improving non-alcoholic steatohepatitis (NASH) through inhibition of inflammasome activation including administering arctigenin and/or arctiin to a subject in need thereof, wherein arctigenin and/or arctiin inhibits release of inflammatory cytokines as IL-1αa, IL-1β, IL-6, IL-18, IL-33, TNF-α, and HMGB1 in the subject after administration.
2. The method for inhibiting inflammasome activation according to claim 1 , wherein only arctiin is administered to the subject.